New Therapies for Ovarian Cancer

Restricted access

In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.

Correspondence: Deborah K. Armstrong, MD, The Skip Viragh Outpatient Cancer Building, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 201 North Broadway, 10th floor, Room 10293, Baltimore, MD 21287.. Email: armstde@jhmi.edu
  • 1.

    Gelmon KA, Tischkowitz M, Mackay H. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12:852861.

    • Search Google Scholar
    • Export Citation
  • 2.

    Domchek SM, Aghajanian C, Shapira-Frommer R. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016;140:199203.

    • Search Google Scholar
    • Export Citation
  • 3.

    Swisher EM, Lin KK, Oza AM. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:7587.

    • Search Google Scholar
    • Export Citation
  • 4.

    Ledermann J, Harter P, Gourley C. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:13821392.

    • Search Google Scholar
    • Export Citation
  • 5.

    Mirza MR, Monk BJ, Herrstedt J. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016;375:21542164.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 437 250 13
PDF Downloads 187 129 31
EPUB Downloads 0 0 0